September 12, 2016: Here are four stocks trading with relatively heavy volume among 56 equities making new 52-week lows in Monday’s session. NYSE advancers led decliners by more than 2 to 1…
September 2, 2016: Here are four stocks trading with relatively heavy volume among 21 equities making new 52-week lows in Friday’s session. NYSE advancers led decliners by nearly 4 to 1 and…
The August 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
The July 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was lower.
Credit Suisse sees the Bristol-Myers Squibb gap with Merck getting even worse, even though it still has robust I-O franchise estimates for Bristol-Myers.
The top analyst upgrades, downgrades and initiations seen on Monday morning include BlackRock, Bristol-Myers, Level 3, NVIDIA, Monsanto and Twenty-First Century Fox.
Bristol-Myers Squibb shares took a nosedive early Friday's following an update in its late-stage Checkmate trial. But Bristol-Myer's failure was a big win for Merck.
Bristol-Myers Squibb released a better-than-expected second-quarter earnings report before the markets opened on Thursday.
The short interest data have been released for the July 15 settlement date. For the selected pharmaceutical stocks, short interest was mixed.
SunTrust Robinson Humphrey feels that the major pharmaceutical companies will outperform the rest of the year, and they cite new products, attractive dividends and solid performance as positives.
The June 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest decreased.
The broad markets are recovering in the wake of the Brexit and it really appears to be one big head fake. We are also realizing that the Brexit was a great opportunity…
The short interest data have been released for the June 15 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials.…
The May 31 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
The ASCO annual meeting is absolutely making waves in the pharmaceutical industry. As a result, analysts are giving their two cents on companies making presentations at the conference.
